We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Has an intensified treatment in the ambulance of patients with acute severe left heart failure improved the outcome?
The aim of this study was to evaluate short- and long-term outcome prior to and after the introduction of a more intensified treatment in the ambulance of patients with acute severe heart failure. Consecutive patients with acute severe heart failure transported by the mobile coronary care unit (MCCU) in the community of Göteborg prior to and after the introduction of an intensified treatment (nitroglycerine, continuous positive airway pressure (CPAP) and furosemide). One hundred and fifty-eight patients were evaluated during each period. The median age was 77 and 76.5 years, respectively, and 52% and 42% were women. The proportion of patients given nitroglycerine in the ambulance was 4% and 68% in the two periods; the proportion of patients treated with furosemide was 13% and 84%, respectively. CPAP was used in less than 1% during period 1 and in 91% during period 2. On admission of the ambulance 60% had fulminant pulmonary oedema during period 1 versus 78% during period 2 (p<0.0001). On admission to hospital the opposite was found, 93% during period 1 versus 76% during period 2 (p<0.0001). The median serum creatinine kinase (CK-MB) maximum activity was 13 microkat/l during period 1 and 8 microkat/l during period 2 (p = 0.007). However, the mortality during the first year remained high during both periods (39.2% and 35.8%, p = 0.64). It is concluded that a more intensive treatment in the ambulance of patients with acute severe heart failure seems to have resulted in an improvement in symptoms during transport and less myocardial damage. However, no significant improvement in long-term mortality was observed.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app